ArticleThe Journal of clinical endocrinology and metabolism2020
Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review.Human reproduction update · 2023Pooled it
- Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women.Human reproduction (Oxford, England) · 2022Pooled it
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Article
- Article
- Associations between pollutants, the regularity of daily sex hormone patterns, and hormone profiles over a complete menstrual cycle.Reproductive toxicology (Elmsford, N.Y.) · 2026Article
- Women with PCOS have a later menopausal transition and a lower prevalence of menopausal symptoms at age 46: A population-based birth cohort study.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Considerations and practical recommendations for identifying perimenopause in longitudinal research.Psychoneuroendocrinology · 2026Review
- Postmortem tissue biomarkers of menopausal transition.Molecular psychiatry · 2026Article
- Longitudinal changes in mammographic density and reproductive hormones during the menopausal transition in middle-aged Korean women: effect modification by obesity.Breast cancer research : BCR · 2025Article
- Using a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG).The Journal of clinical endocrinology and metabolism · 2025Article
- The role of anti-Müllerian hormone: insights into ovarian reserve, primary ovarian insufficiency, and menopause prediction.Endocrine · 2025Review
- Negligible serum anti-Müllerian hormone levels and successfully spontaneous pregnancy three times: a case report.Journal of ovarian research · 2025Article
- Heavy Metals and Trajectories of Anti-Müllerian Hormone During the Menopausal Transition.The Journal of clinical endocrinology and metabolism · 2024Article
- Circulating anti-Müllerian hormone levels in pre-menopausal women: novel genetic insights from a genome-wide association meta-analysis.Human reproduction (Oxford, England) · 2024Article
- Making a good egg: human oocyte health, aging, and in vitro development.Physiological reviews · 2023Review
- Body Composition Changes Over the Menopausal Transition in Women With and Without Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Antimüllerian Hormone as a Tool to Predict the Age at Menopause.Geriatrics (Basel, Switzerland) · 2023Article
- Menopause and women's cardiovascular health: is it really an obvious relationship?Archives of medical science : AMS · 2023Article
- Anti-Müllerian Hormone and Cardiometabolic Disease in Women: A Two-Sample Mendelian Randomization Study.Reviews in cardiovascular medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundA test that helps predict the time to the final menstrual period (FMP) has been sought for many years.
objectiveTo assess the ability of antimullerian hormone (AMH) measurements to predictions the time to FMP.
designProspective longitudinal cohort study.
settingThe Study of Women's Health Across the Nation. PARTICIPANTS AND MEASUREMENTS: AMH and FSH were measured in 1537 pre- or early perimenopausal women, mean age 47.5 ± 2.6 years at baseline, then serially until 12 months of amenorrhea occurred. AMH was measured using a 2-site ELISA with a detection limit of 1.85 pg/mL.
main outcome measureAreas under the receiver operating curves (AUC) for AMH-based and FSH-based predictions of time to FMP, stratified by age. Probabilities that women would undergo their FMP in the next 12, 24, or 36 months across a range of AMH values were assessed.
resultsAUCs for predicting that the FMP will occur within the next 24 months were significantly greater for AMH-based than FSH-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within the next 12 months ranged from 51% at h<48 years of age to 79% at ≥51 years. The probability that a woman with an AMH >100 pg/mL would not undergo her FMP within the next 12 months ranged from 97% in women <48 years old to 90% in women ≥51 years old.
conclusionsAMH measurement helps estimate when a woman will undergo her FMP, and, in general, does so better than FSH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.